Navigation Links
ACORN's Success in Delivering Top Quality Research Portfolio to Community-Based Oncology Practices Presented at Annual Investigator Meeting
Date:3/2/2009

MEMPHIS, Tenn., March 2 /PRNewswire-USNewswire/ -- Accelerated Community Oncology Research Network (ACORN(TM)), an oncology focused research network, announced today the highlights of its annual Principal Investigators' Meeting held in Scottsdale, AZ in February. Medical oncologists from community-based oncology practices throughout the United States met to discuss the latest cancer research advances, emerging treatment trends, as well as promising new molecules in the drug pipeline.

(Logo: http://www.newscom.com/cgi-bin/prnh/20071112/CLM151LOGO )

2008 represented a banner year for ACORN and its network members. 74 different sponsors, representing 93 industry-sponsored trials, engaged the ACORN Network. Additionally, 21 ACORN investigator initiated trials were open in 2008. The ACORN portfolio included studies of 41 different investigational agents in 2008. 62% of ACORN's 2008 studies were Phase II with the majority of the trials focusing on cancers of the lung, breast, ovary, colon/rectum, or pancreas. ACORN also delivered research opportunities for less frequently seen cancers to its member practices to make treatments of all cancer types available.

"Commitment to research excellence is integral to the ACORN process as is thorough education of all staff members. We continue to identify new processes to facilitate rapid deployment of clinical trials to community-based oncology practices while experiencing banner growth," remarked Edward J. Stepanski, PhD, COO, ACORN.

Practicing oncologists in the ACORN Network serve as Tumor Committee Chairs. Those presenting at the 2009 Meeting included Mark Keaton, MD, Augusta Oncology Associates, Augusta, GA, Gastroenterology; Lee Schwartzberg, MD, FACP, The West Clinic, Memphis, TN, Breast Cancer; Frederick Schnell, MD, FACP, Central Georgia Cancer Care, Macon, GA, Lymphoma; Brian Samuels, MD, FACP, FCP(SA), Kootenai Cancer Center, Coeur d'Alene, ID, Melanoma, Sarcoma, and Rare Cancer Trials; Johnetta Blakely, MD, The West Clinic, Memphis, TN, Phase 1 Trials; David Henry, MD, Pennsylvania Oncology Hematology Associates, Philadelphia, PA, Supportive Care Trials; and Brad Somer, MD, The West Clinic, Memphis, TN, Genitourinary Trials.

The ACORN Network seeks to make clinical research an integral part of community-based cancer care by giving every patient an equal opportunity to participate in clinical research. By making research a vital part of clinical operations and using technology to streamline the process, ACORN enhances the speed, accuracy, and productivity of clinical trial operations. More rapid development time for new agents results in providing more effective care to benefit patients faster than previously possible. ACORN provides Contracting, Budgeting, Regulatory Affairs, Project Management, Data Management, Quality Assurance, Statistical Analysis, Medical Writing, and Site Development to its participating members and pharmaceutical sponsors.

"In 2009, ACORN will accelerate its commitment to oncology research by expanding opportunities for both members and sponsors," announced Lee S. Schwartzberg, MD, FACP, President of ACORN.

For additional information, contact Liz Conway, Director of Marketing and Corporate Services, 901-259-0878 or visit www.ACORNresearch.net.

Accelerated Community Oncology Research Network, Inc.(TM) (ACORN)

ACORN focuses on oncology exclusively. ACORN offers centralized clinical trial services, scientific analysis, and is a full-service Contract Research Organization (CRO), providing contract and budgeting services; fostering accrual of subjects at the site level; collecting data and monitoring its accuracy; and working seamlessly with both trial sponsors and participating practices.

    Contact Information:
    Liz Conway
    (901) 435-5570
    lconway@sosacorn.com
    www.ACORNresearch.net

    Deborah D. Coble
    901-683-0055 x1312
    dcoble@sosacorn.com


'/>"/>
SOURCE Accelerated Community Oncology Research Network, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Kenyan malaria success strengthens call for free insecticide-treated nets for all
2. Eligard(R) six-month formulation successfully completes European approval procedure
3. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
4. Milestone Scientific Announces Successful Completion of its Collaboration Agreement With Carticept Medical
5. Texas Largest Physician Carrier Announces 5th Successive Rate Cut on Anniversary of Lawsuit Reform
6. Bacteria successful in cancer treatment
7. Congress Poised to Add Millions of Uninsured Children to Successful, Bipartisan Health Plan
8. Success of Shape-Up Somerville Childhood Obesity Intervention to be Presented at the Friedman School Symposium at Tufts, October 29-31, 2007 - Boston
9. Success of Shape Up Somerville childhood obesity intervention to be presented
10. Cell growth technology promises more successful drug development
11. CIGNA Group Insurance Celebrates Return to Work Success During National Rehabilitation Awareness Week
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... December 06, 2016 , ... It can be argued that people these days ... members as they do for their human friends and family. As pets have ... highest quality and most innovative pet products has also increased. , For ...
(Date:12/6/2016)... ... December 06, 2016 , ... The Behavioral Health Center ... recognizing the organization as a top behavioral service provider in the country. The ... quality, staff satisfaction and qualifications, and consumer satisfaction. These areas are measured via ...
(Date:12/6/2016)... ... December 06, 2016 , ... Gateway Analytical, one of ... particle counting and sizing services for USP 788 and 789 particulate standards compliance. ... as a response to the needs of pharmaceutical and medical device manufacturers, who ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... the much-anticipated HydroFX for Water®. This first-of-its-kind water-soluble powder supplement has a ... world’s most powerful antioxidants, molecular hydrogen, HydroFX for Water transforms every day ...
(Date:12/6/2016)... Vancouver, B.C., Canada (PRWEB) , ... December 06, ... ... Consultants (STC) announce the availability of the newly updated International Audit Protocol Consortium ... world use IAPC EHS audit protocols to understand the scope of their EHS ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... N.J. , Dec. 5, 2016  Daiichi ... preliminary safety and efficacy data from a phase ... MDM2 inhibitor, suggesting that DS-3032 may be a ... myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). ... the phase 1 study of DS-3032 were presented in ...
(Date:12/5/2016)... -- BD (Becton, Dickinson and Company) (NYSE: BDX ... an enhanced technology platform designed with the ability to ... Pyxis™ and Alaris™ systems, at this year,s American ... being held in Las Vegas ... that approximately 68 percent of medication errors occur during ...
(Date:12/5/2016)... , Dec. 5, 2016 Eisai Inc. ... at the 2016 Annual Meeting of the American Epilepsy ... CIII, is indicated as an adjunctive therapy for the ... secondarily generalized seizures and primary generalized tonic-clonic seizures (PGTC) ... age and older. Please see Important Safety Information for ...
Breaking Medicine Technology: